{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:21:13Z","timestamp":1787242873105,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.oftale.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T11:56:48Z","timestamp":1716033408000},"page":"400-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country"],"prefix":"10.1016","volume":"99","author":[{"given":"C.","family":"Zuluaga-Botero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mart\u00ednez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2024.05.005_bib0005","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.4103\/IJO.IJO_889_23","article-title":"The impact after 20 years of an early detection program for severe retinopathy of prematurity in a Latin American city","volume":"71","author":"Zuluaga-Botero","year":"2023","journal-title":"Indian J Ophthalmol."},{"key":"10.1016\/j.oftale.2024.05.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.113913","article-title":"Clinical risk factors for retinopathy of prematurity reactivation after intravitreal anti-vascular endothelial growth factor injection","author":"Lee","year":"2024","journal-title":"J Pediatr."},{"key":"10.1016\/j.oftale.2024.05.005_bib0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.oftal.2023.04.009","article-title":"Resultados funcionales de tratamiento con bevacizumab intrav\u00edtreo en pacientes con retinopat\u00eda del prematuro","volume":"98","author":"Sanju\u00e1n Riera","year":"2023","journal-title":"Arch Soc Esp Oftalmol."},{"key":"10.1016\/j.oftale.2024.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2024.05.005_bib0025","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2024.05.005_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1159\/000531541","article-title":"A meta-analysis of neurodevelopmental outcomes following intravitreal bevacizumab for the treatment of retinopathy of prematurity","volume":"120","author":"Baiad","year":"2023","journal-title":"Neonatology."},{"key":"10.1016\/j.oftale.2024.05.005_bib0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2023","journal-title":"Ital J Pediatr."},{"key":"10.1016\/j.oftale.2024.05.005_bib0040","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol."},{"key":"10.1016\/j.oftale.2024.05.005_bib0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3341\/kjo.2018.0011","article-title":"Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes","volume":"32","author":"Kang","year":"2018","journal-title":"Korean J Ophthalmol."},{"key":"10.1016\/j.oftale.2024.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and very low-dose bevacizumab for retinopathy of prematurity","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology."},{"key":"10.1016\/j.oftale.2024.05.005_bib0055","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11095-016-1940-2","article-title":"Hydrodynamic radii of ranibizumab, aflibercept and bevacizumab measured by time-resolved phosphorescence anisotropy","volume":"33","author":"Hirvonen","year":"2016","journal-title":"Pharm Res."},{"key":"10.1016\/j.oftale.2024.05.005_bib0060","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.oftale.2024.05.005_bib0065","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina."}],"updated-by":[{"DOI":"10.1016\/j.oftale.2025.04.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579424000884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579424000884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T22:27:51Z","timestamp":1724970471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579424000884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2173579424000884"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2024.05.005","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2024.03.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}